These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 18483085)

  • 1. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
    Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
    Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
    Hong R; Halama J; Bova D; Sethi A; Emami B
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.
    Devic S; Mohammed H; Tomic N; Aldelaijan S; De Blois F; Seuntjens J; Lehnert S; Faria S
    Br J Radiol; 2016 Jun; 89(1062):20150388. PubMed ID: 27007269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining a radiotherapy target with positron emission tomography.
    Black QC; Grills IS; Kestin LL; Wong CY; Wong JW; Martinez AA; Yan D
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1272-82. PubMed ID: 15519800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography.
    Hanna GG; van Sörnsen de Koste JR; Dahele MR; Carson KJ; Haasbeek CJ; Migchielsen R; Hounsell AR; Senan S
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):e71-80. PubMed ID: 22445302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
    de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
    J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
    Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Glut-1 glucose transporter expression with.
    Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
    Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.